Sort   by:  
 Page size 
TranscriptomicsWnt5A Enhances Resistance of Melanoma Cells to Targeted BRAF Inhibitors
About half of all melanomas harbor a constitutively active mutant BRAFV600E/K kinase that can be selectively inhibited by targeted BRAF inhibitors (BRAFi). While patients treated with BRAFi initially exhibit measurable clinical improvement, the majority of patients eventually develop drug resistance...
ORGANISM(S): Homo sapiens 
2014-03-06 | E-GEOD-55583 | biostudies-arrayexpress
GenomicsAndrogen Receptor is a Determinant of Melanoma BRAFi/MEKi Resistance [Clariom_1]
Androgen Receptor is a Determinant of Melanoma BRAFi/MEKi Resistance [Clariom_1]
PRJNA819952 | ENA
GenomicsAndrogen Receptor is a Determinant of Melanoma BRAFi/MEKi Resistance [Clariom_2]
Androgen Receptor is a Determinant of Melanoma BRAFi/MEKi Resistance [Clariom_2]
PRJNA973594 | ENA
GenomicsAndrogen Receptor is a Determinant of Melanoma BRAFi/MEKi Resistance [ChIP-Seq]
Androgen Receptor is a Determinant of Melanoma BRAFi/MEKi Resistance [ChIP-Seq]
PRJNA973595 | ENA
GenomicsIbrutinib blocks YAP1 activation and reverses BRAFi resistance in melanoma cells
Ibrutinib blocks YAP1 activation and reverses BRAFi resistance in melanoma cells
PRJNA608923 | ENA
ProteomicsProteomics of BRAFi-treated endothelial cells
Targeted therapies against mutant BRAF are effectively used in combination with MEK inhibitors (MEKi) to treat advanced melanoma. However, treatment success is affected by resistance and adverse events (AEs). Approved BRAF inhibitors (BRAFi) show high levels of target promiscuity, which can contribu...
ORGANISM(S): Homo sapiens (Human) 
2024-06-01 | PXD052251 | Pride
Human Phosphoproteomics Endothelial cells Brafi Vemurafenib 
ProteomicsPhosphoproteomics of BRAFi-treated endothelial cells
Targeted therapies against mutant BRAF are effectively used in combination with MEK inhibitors (MEKi) to treat advanced melanoma. However, treatment success is affected by resistance and adverse events (AEs). Approved BRAF inhibitors (BRAFi) show high levels of target promiscuity, which can contribu...
ORGANISM(S): Homo sapiens (Human) 
2024-06-01 | PXD052259 | Pride
Human Phosphoproteomics Endothelial cells Brafi Vemurafenib 
TranscriptomicsAndrogen Receptor is a Determinant of Melanoma BRAFi/MEKi Resistance [Clariom_1]
The majority of BRAFV600 mutant melanomas regress in response to BRAF/MEK inhibitors (BRAFi/MEKi). Yet nearly all relapse within the first two years. Most BRAFi/MEKi-resistant tumors are cross-resistant to immunotherapies, highlighting the need to prevent and circumvent resistance. We recently showe...
ORGANISM(S): Homo sapiens 
2023-08-03 | GSE199405 | GEO
TranscriptomicsAndrogen Receptor is a Determinant of Melanoma BRAFi/MEKi Resistance [Clariom_2]
The majority of BRAFV600 mutant melanomas regress in response to BRAF/MEK inhibitors (BRAFi/MEKi). Yet nearly all relapse within the first two years. Most BRAFi/MEKi-resistant tumors are cross-resistant to immunotherapies, highlighting the need to prevent and circumvent resistance. We recently showe...
ORGANISM(S): Homo sapiens 
2023-08-03 | GSE232693 | GEO
GenomicsAndrogen Receptor is a Determinant of Melanoma BRAFi/MEKi Resistance [ChIP-Seq]
The majority of BRAFV600 mutant melanomas regress in response to BRAF/MEK inhibitors (BRAFi/MEKi). Yet nearly all relapse within the first two years. Most BRAFi/MEKi-resistant tumors are cross-resistant to immunotherapies, highlighting the need to prevent and circumvent resistance. We recently showe...
ORGANISM(S): Homo sapiens 
2023-08-03 | GSE232690 | GEO
Sort   by:  
 Page size